Verastem Inc.

VSTM | NASDAQ

Price Alert Chart Builder DCF Calculator

$7.99

+$0.55 (+7.39%)

At close: Sep 21, 2026, 4:00 PM ET

$8.05

+$0.06 (+0.70%)

Pre-market: Sep 22, 2026, 4:03 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+7.39%

(1D)

Rating

Updated: Aug 20, 2026

33.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $702.11M

1D Range

7.50 8.04

52W Range

3.43 10.82

Valuation (TTM)

PE -3.25

PB 14.05

EV/EBITDA -3.23

Valuation (NTM)

Forward PE N/A

Forward PEG 0.35

Price Target $14.43

Cash Flow

FCF Yield -23.3%

SBC Adj. FCF Yield -24.7%

SBC Impact -5.9%

Margins

Gross Margin 86.7%

Operating Margin -182.6%

FCF Margin -186.8%

Growth (CAGR)

Revenue 3Y | 5Y 116.7% | 1.6%

Dil EPS 3Y | 5Y 13.6% | 14.8%

FCF 3Y | 5Y -23.9% | -26.4%

Returns

ROA -98.2%

ROE -467.5%

ROIC -118.5%

Financial Health

Net Cash

$59.97M

Current Ratio 2.25

Interest Coverage -108.26

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-676...

Sector Healthcare

Industry Biotechnology

Employees 102

IPO Date Jan 26, 2012

Website www.verastem.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 3, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$14

Upside

+75.22%

Buy (6)

Hold (0)

Sell (0)

Analyst Details ➞